Perspectives of Alzheimer's disease treatments.
Davis
John B
JB
Neurology and GI CEDD, GlaxoSmithKline R&D Ltd, Harlow, UK. john.b.davis@gsk.com
Bountra
C
C
Richardson
J
J
D000544:Alzheimer Disease / Q000150:complications / Q000276:immunology / Q000378:metabolism / Q000628:therapy*; D000682:Amyloid / Q000187:drug effects / Q000378:metabolism; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001526:Behavioral Symptoms / Q000188:drug therapy / Q000209:etiology; D003072:Cognition Disorders / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D056747:Immunomodulation
D000682:Amyloid; D000894:Anti-Inflammatory Agents, Non-Steroidal; D014150:Antipsychotic Agents